개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한비뇨기과학회 Investigative and Clinical Urology Investigative and Clinical Urology Vol.61 No.6 KCI Accredited Journals
- 발행연도
- 2020.1
- 수록면
- 600 - 606 (7page)
이용수
Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
초록· 키워드
오류제보하기
Purpose: To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics. Materials and Methods: We retrospectively reviewed the data of 566 male patients aged ≥40 with OAB symptoms between January 2017 and June 2018. They were treated with low-dose antimuscarinics for at least 4 weeks and showed poor efficacy; therefore, they were switched to standard dose antimuscarinic treatment (5 mg of solifenacin) for ≥12 weeks. The international prostate symptom score (IPSS) and overactive bladder symptom score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Post void residual urine volume (PVR) was also recorded. Results: The median age, body mass index, and prostate-specific antigen levels were 69.0 years, 24.2 kg/m2, and 1.24 ng/dL, respectively. The mean value of the total IPSS and OABSS significantly decreased between V0 and V2 (from 16.73 to 13.69 and 7.33 to 5.34, respectively, all p<0.001). All component scores from each questionnaire demonstrated a significant decrease except for numbers three and six on the IPSS questionnaire. PVR was increased from V0 to V2 (36.40 to 68.90 mL, p=0.015). Four and nine patients experienced constipation and thirst, respectively, and all adverse effects were graded as ≤2. Conclusions: Standard dose antimuscarinic treatment using solifenacin (5 mg) may be a safe and effective treatment for patients with OAB symptoms refractory to low-dose antimuscarinic treatment.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Abrams P / 2003 / The standardisation of terminology in lower urinary tract function : report from the standardisation sub-committee of the International Continence Society / Urology 61:37~49
Cartwright R / 2011 / Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder / BJU Int 107:1612~1617
조강준 / 2011 / Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia / International Neurourology Journal 15(3):152~157
Montorsi F / 2011 / The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study / BJU Int 107:1426~1431
Singh I / 2015 / ‘Tamsulosin and darifenacin’ versus ‘tamsulosin monotherapy’ for ‘BPH with accompanying overactive bladder’ / J Clin Diagn Res 9:PC08~PC11
Cartwright R / 2011 / Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder / BJU Int 107:1612~1617
조강준 / 2011 / Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia / International Neurourology Journal 15(3):152~157
Montorsi F / 2011 / The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study / BJU Int 107:1426~1431
Singh I / 2015 / ‘Tamsulosin and darifenacin’ versus ‘tamsulosin monotherapy’ for ‘BPH with accompanying overactive bladder’ / J Clin Diagn Res 9:PC08~PC11
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
International Neurourology Journal
2015 .01
-
Factors affecting medication discontinuation in patients with overactive bladder symptoms
Obstetrics & Gynecology Science
2015 .01
-
Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
International Neurourology Journal
2016 .12
-
Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment
Investigative and Clinical Urology
2017 .01
-
Diagnostic Tool for Assessing Overactive Bladder Symptoms: Could the International Prostate Symptom Storage Subscore Replace the Overactive Bladder Symptom Score?
International Neurourology Journal
2016 .01
-
과민성방광의 새로운 약물치료: 미라베그론과보툴리눔 독소
대한의사협회지
2016 .01
-
Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients
International Neurourology Journal
2017 .01
-
Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result
International Neurourology Journal
2015 .01
-
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
Investigative and Clinical Urology
2017 .01
-
Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms
International Neurourology Journal
2016 .01
-
Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors
Investigative and Clinical Urology
2017 .01
-
Influence of solifenacin on the improvement of storage symptoms in the early period after photoselective vaporization of the prostate
Investigative and Clinical Urology
2019 .01
-
The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?
International Neurourology Journal
2018 .01
-
기침을 동반한 과민성 방광 증후군에 대한 한방 치료 1례
대한한방내과학회지
2020 .01
-
Effects of Overactive Bladder Symptoms in Stroke Patients’ Health Related Quality of Life and Their Performance Scale
Annals of Rehabilitation Medicine
2017 .01
-
Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality
Journal of Korean Medical Science
2017 .01
-
Assessment of Proportion of Hidden Patients Having Symptoms of Overactive Bladder and Why Has It Been Hidden in Female Outpatients Admitted to Hospital
International Neurourology Journal
2016 .01
-
Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
International Neurourology Journal
2018 .01
-
Drug therapy of overactive bladder - What is coming next?
Investigative and Clinical Urology
2015 .01
-
Efficacy and Tolerability of Solifenacin Fumarate with Overactive Bladder Patients: A Multicenter Observational Study
Urogenital Tract Infection
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0